NASDAQ : BRNS
Barinthus Biotherapeutics plc — Key statistics
Healthcare · Biotechnology · United States
Last price 0.7401 USD (At close: Sep 8, 2026) · Market cap 30.23M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 30.23M |
| Enterprise Value | -18.77M |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 40.85M |
| Shares Change (YoY) | +1.88% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 11.74% |
| Owned by Institutions (%) | 30.88% |
| Float | 27.26M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.53 |
| P/TBV Ratio | 0.74 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.54 |
| Quick Ratio | 5.33 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -606.23 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -52.38% |
| Return on Assets (ROA) | -18.99% |
| Return on Invested Capital (ROIC) | -22.08% |
| Return on Capital Employed (ROCE) | -45.59% |
| Weighted Average Cost of Capital (WACC) | 1.84% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.98M |
| Employee Count | 14 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -167,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.36 |
| 52-Week Price Change | -35.48% |
| 50-Day Moving Average | 0.63 |
| 200-Day Moving Average | 0.66 |
| Relative Strength Index (RSI) | 60.26 |
| Average Volume (20 Days) | 83,435 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 9,037 |
| Short Previous Month | 45,910 |
| Short % of Shares Out | 0.04% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.25 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | 8.59M |
| Operating Income | -32.13M |
| Pretax Income | -41.97M |
| Net Income | -41.77M |
| EBITDA | -31.24M |
| EBIT | -32.13M |
| Earnings Per Share (EPS) | -$1.02 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 59.30M |
| Total Debt | 10.30M |
| Net Cash | 49.00M |
| Net Cash Per Share | $1.20 |
| Equity (Book Value) | 57.13M |
| Book Value Per Share | 1.40 |
| Working Capital | 51.85M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -26.43M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 886,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -26.43M |
| FCF Per Share | -$0.65 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.88% |
| Shareholder Yield | -1.88% |
| Earnings Yield | -127.81% |
| FCF Yield | -80.86% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $6.00 |
| Price Target Difference | 710.70% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |